ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Show more
Location: 2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, United States | Website: https://prokidney.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
658.8M
52 Wk Range
$0.46 - $7.13
Previous Close
$2.19
Open
$2.19
Volume
918,759
Day Range
$2.13 - $2.25
Enterprise Value
42.5M
Cash
271.7M
Avg Qtr Burn
-27.94M
Insider Ownership
25.38%
Institutional Own.
28.56%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Phase 3 Data readout | |
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Phase 2 Update | |
Rilparencel (REACT®) Details Chronic kidney disease, Diabetes | Phase 2 Update | |
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Failed Discontinued |
